Study of Hangeshasinto and Rikkunshito for Irritable bowel syndrome

Study of Hangeshasinto and Rikkunshito for Irritable bowel syndrome - Kampo medicine for Irritable bowel syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020981

Enrollment

Registered

2016-02-23

Start date

2016-03-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable bowel syndrome (IBS) with diarrhea

Interventions

Hangesyashinto 5.0g/day, daily twice, for 28 days Rikkunshito 5.0g/day, daily twice, for 28 days

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Irritable bowel syndrome diarrhea type Not frail

Exclusion criteria

Exclusion criteria: Tumor, inflammatory bowel disease Patients has took laxative, antidiarrheal agents, or probiotics within 1 week before the study Patient has took antibiotics, anti-inflammatory agents, or steroid within 6 week before the study Patient is under medication with anticholinergic drugs, antimuscarinic drugs, proton pump inhibitor, or minor tranquilizer Patient has past history of bowel operation (operation of appendicitis is applicable) hypokalemia (K under 3.5mEq/l), liver dysfunction (AST over twice the reference value)

Design outcomes

Primary

Measure	Time frame
improvement of symptom of IBS at the end of 28-day drug intervention	—

Countries

Japan

Contacts

Public ContactAkiko Kuwabara

Tohoku University Hospital Department of Education and Support for Regional Medicine, Department of Kampo Medicine

akiko.kuwabara.d7@tohoku.ac.jp0227177507

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026